CMS Connect Login:

Login Assistance


Since April the Chicago Medical Society has partnered with Metro Infectious Disease Consultants on a convalescent plasma therapy program that has served community hospitals caring for critically ill patients with COVID-19.

The FDA recently approved another clinical trial using the investigational therapy on patients infected with the SARS-CoV-2 with mild to moderate symptoms but not requiring hospitalization.

As such, CMS and MIDC are partnering on that trial and recruiting patients for possible participation in the study. We encourage you to refer patients who meet the criteria outlined below. All patients will receive a unit of convalescent plasma or standard of care throughout the trial period.
Patients who meet the following criteria may be eligible for the study:
Inclusion Criteria:
1. Adults with laboratory confirmed diagnosis of infection with SARS-CoV-2
2. Symptoms of COVID -19
3. Ambulatory Outpatient

Patient compensation is available for participation. Patients to be evaluated: 844-227-6432 (844-CCP-MIDC)

List of Contacts:  
Russell Petrak, MD
Robert Fliegelman, DO
Nicholas Van Hise, PharmD
Nathan Skorodin, PharmD Identifier: NCT0443805
WIRB® Protocol #20201789

This FDA approved study is funded and administered by Metro Infectious Disease Consultants (MIDC)


Document Actions

Join CMS

Why join?  The Chicago Medical Society offers many benefits, including career placement, advocacy, networking, and member to member collaboration. Click here to explore all the benefits of membership.

CMS Connect

CMS Connect is an exclusive community that allows members to discuss the issues impacting their practices today. Visit CMS Connect today.